{"id":41262,"date":"2021-09-17T07:32:00","date_gmt":"2021-09-17T07:32:00","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=41262"},"modified":"2021-12-15T22:24:58","modified_gmt":"2021-12-15T22:24:58","slug":"start-study-call-for-participants-to-attend-final-visit-please-help","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/41262","title":{"rendered":"START study: call for participants to attend final visit \u2013 please help…"},"content":{"rendered":"
\n
\"\"<\/a>

Poster\/flyer to download.<\/p><\/div>\n

Simon Collins, HIV i-Base<\/span><\/strong><\/p>\n<\/div>\n

\n

Researchers from the large international START study are contacting study participants for a final follow-up visit. <\/span><\/strong><\/p>\n<\/div>\n

\n

Although HIV sites are leading on this, many people may have changed their clinic during what is now a 12 year study.<\/span><\/p>\n<\/div>\n

\n

Also, while the main results were reported in 2015, additional funding supported extending the follow up. This unique data set will now look at long-term risks from delaying ART.<\/span><\/p>\n<\/div>\n

\n

\"\"<\/strong>This is not just an academic request. These results from the final follow-up have important clinical relevance in 2021.\u00a0<\/span><\/p>\n

Late diagnosis is still a serious problem in all countries. More than 40% of people in the UK are still diagnosed with a CD4 count <350 cells\/mm3<\/sup>. And this is associated with an 8-fold risk of mortality. [1]<\/p>\n<\/div>\n

\n

comment<\/span><\/h3>\n<\/div>\n
\n

Your help now is really appreciated \u2013 whether as a participant or study site. <\/span><\/strong><\/p>\n<\/div>\n

\n

In the UK sites around 300 participants helped this important research.<\/span><\/strong><\/p>\n<\/div>\n

\n

If you were part of START please contact your current clinic who will arrange everything.<\/span><\/strong><\/p>\n<\/div>\n

\n

You can also email Claire Rappoport, the community coordinator for the study network:
\n<\/span>insightclairer@gmail.com<\/strong><\/p>\n<\/div>\n

\n

Thank you…<\/span><\/strong><\/p>\n<\/div>\n

\n

Additional background<\/h2>\n<\/div>\n
\n

In 2015, the START study reported clinical benefits of early ART, even when CD4 counts were above 500 cells\/mm3.<\/sup>\u00a0At this level HIV was thought to cause few serious problems. [2]<\/span><\/p>\n<\/div>\n

\n

The evidence was so important that the WHO announced plans to change the guidelines within weeks. It also show the importance of universal access globally. [3, 4]<\/span><\/p>\n<\/div>\n

\n

Compared to starting when the CD4 count was still high at 350 cells\/mm3<\/sup>, early ART halved the risk of serious infections, including mortality. These results showed ART was safer than expected and that untreated HIV was more dangerous with a high CD4 count that previously though. And START found this 18 months earlier than predicted.<\/span><\/p>\n<\/div>\n

\n

References<\/span><\/p>\n<\/div>\n

\n
    \n
  1. Public Health England. <\/span>Trends in HIV testing, new diagnoses and people receiving HIV-related care in the United Kingdom: data to the end of December 2019. Health Protection Report 14(20). (3 November 2020).
    \nhttps:\/\/www.gov.uk\/government\/publications\/hiv-in-the-united-kingdom<\/a> (download page)
    \n    https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/959330\/hpr2020_hiv19.pdf (<\/a>PDF)<\/li>\n
  2. Early START results recommend ART for all study participants: starting HIV meds when the CD4 count is above 500 reduces AIDS-related events. HTB (1 June 2015).
    \nhttps:\/\/i-base.info\/htb\/28261    https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/959330\/hpr2020_hiv19.pdf<\/a> (PDF)<\/li>\n
  3. New directions in the 2015 WHO ART guidelines. (1 August 2015).
    \n    https:\/\/i-base.info\/htb\/28597<\/a><\/li>\n
  4. WHO guidelines for when to start ART and use of PrEP (September 2015). HTB (October 2015).
    \n    https:\/\/i-base.info\/htb\/28949<\/a><\/li>\n<\/ol>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

    Simon Collins, HIV i-Base Researchers from the large international START study are contacting study participants for a final follow-up visit. Although HIV sites are leading on this, many people may have changed their clinic during what is now a 12 …<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[189],"tags":[],"class_list":["post-41262","post","type-post","status-publish","format-standard","hentry","category-research-studies"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/41262","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=41262"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/41262\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=41262"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=41262"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=41262"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}